Essentials of filoviral load quantification

The Lancet Infectious Diseases

Volumn 16, Issue 7, 2016, Pages e134-e138

  Cnops, Lieselotte ^a   van Griensven, Johan ^a   Honko, Anna N ^b   Bausch, Daniel G ^c   Sprecher, Armand ^d   Hill, Charles E ^e   Colebunders, Robert ^f   Johnson, Joshua C ^b   Griffiths, Anthony ^g   Palacios, Gustavo F ^h   Kraft, Colleen S ⁱ   Kobinger, Gary ^j   Hewlett, Angela ^k   Norwood, David A ^h   Sabeti, Pardis ^l   Jahrling, Peter B ^b   Formenty, Pierre ^c   Kuhn, Jens H ^b   Ariën, Kevin K ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d MÉDECINS SANS FRONTIÈRES   (Belgium)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^h UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MANITOBA   (Canada)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l HARVARD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; DISEASE SEVERITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FILOVIRUS; FILOVIRUS INFECTION; HUMAN; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SURVIVAL; VIRUS LOAD; VIRUS TRANSMISSION; WEST AFRICAN; AFRICA; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; PROCEDURES;

AFRICA, WESTERN; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 84975226380     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30063-9     Document Type: Review

References (56)

1. Kuhn JH Ebolavirus and marburgvirus infections. Harrison's principles of internal medicine 2015, 1323-1329. McGraw-Hill Education, Columbus, OH, USA. 19th edn. D.L. Kasper, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo (Eds.).
2. Kuhn JH. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch Virol Suppl. 20: 13-360.
3. Ebola maps: 2015 WHO, (accessed Dec 11, 2015). http://www.who.int/csr/disease/ebola/maps-2015/en/.
4. Drosten C, Kümmerer BM, Schmitz H, Günther S Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res 2003, 57:61-87.
5. Walker NF, Brown CS, Youkee D, et al. Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015. Euro Surveill 2015, 20. PII:21073.
6. Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 2015, 386:867-874.
7. Nouvellet P, Garske T, Mills HL, et al. The role of rapid diagnostics in managing Ebola epidemics. Nature 2015, 528:S109-S116.
8. Racsa LD, Kraft CS, Olinger GG, Hensley LE Viral hemorrhagic fever diagnostics. Clin Infect Dis 2016, 62:214-219.
9. Fitzpatrick G, Vogt F, Moi Gbabai OB, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières ebola case management centre, Kailahun, Sierra Leone, June-October 2014. J Infect Dis 2015, 212:1752-1758.
10. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014, 371:2092-2100.
11. Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004, 78:4330-4341.
12. Lanini S, Portella G, Vairo F, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 2015, 125:4692-4728.
13. de La Vega MA, Caleo G, Audet J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest 2015, 125:4421-4428.
14. Park DJ, Dudas G, Wohl S, et al. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell 2015, 161:1516-1526.
15. Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015, 372:40-47.
16. Weidmann M, Hufert FT, Sall AA Viral load among patients infected with marburgvirus in Angola. J Clin Virol 2007, 39:65-66.
17. Kupferschmidt K, Cohen J Ebola drug trials lurch ahead. Science 2015, 347:701-702.
18. van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis 2016, 62:69-74.
19. Chowell G, Viboud C Ebola vaccine trials: a race against the clock. Lancet Infect Dis 2015, 15:624-626.
20. Sissoko D, Folkesson E, Abdoul Ml, et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26, 2015. Abstract number 103-ALB.
21. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016, 13:e1001967.
22. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014, 345:1369-1372.
23. Hoenen T, Safronetz D, Groseth A, et al. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 2015, 348:117-119.
24. Carroll MW, Matthews DA, Hiscox JA, et al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in west Africa. Nature 2015, 524:97-101.
25. Mackay IM, Arden KE Ebola virus in the semen of convalescent men. Lancet Infect Dis 2015, 15:149-150.
26. Christie A, Davies-Wayne GJ, Cordier-Lassalle T, et al. Possible sexual transmission of Ebola virus-Liberia, 2015. MMWR Morb Mortal Wkly Rep 2015, 64:479-481.
27. Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 2015, 373:2448-2454.
28. Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors-preliminary report. N Engl J Med 2015, 10.1056/NEJMoa1511410.
29. Yeh S, Varkey JB, Crozier I Persistent Ebola virus in the eye. N Engl J Med 2015, 373:1982-1983.
30. Murphy H British nurse makes "full recovery" from reactivated Ebola virus. BMJ 2015, 351:h6133.
31. Moreau M, Spencer C, Gozalbes JG, et al. Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro Surveill 2015, 20. pii:21017.
32. Akerlund E, Prescott J, Tampellini L Shedding of Ebola virus in an asymptomatic pregnant woman. N Engl J Med 2015, 372:2467-2469.
33. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by Gram-negative septicemia. N Engl J Med 2014, 371:2394-2401.
34. Kuming BS, Kokoris N Uveal involvement in Marburg virus disease. Br J Ophthalmol 1977, 61:265-266.
35. Martini GA, Schmidt HA Spermatogene Übertragung des "Virus Marburg" (Erreger der "Marburger Affenkrankheit"). Klin Wochenschr 1968, 46:398-400.
36. Borchert M, Muyembe-Tamfum JJ, Colebunders R, Libande M, Sabue M, Van Der Stuyft P A cluster of Marburg virus disease involving an infant. Trop Med Int Health 2002, 7:902-906.
37. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007, 196(suppl 2):S142-S147.
38. Burd EM Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 2010, 23:550-576.
39. Bustin SA, Mueller R Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005, 109:365-379.
40. Spengler JR, McElroy AK, Harmon JR, Ströher U, Nichol ST, Spiropoulou CF Relationship between Ebola virus real-time quantitative polymerase chain reaction-based threshold cycle value and virus isolation from human plasma. J Infect Dis 2015, 212(suppl 2):S346-S349.
41. Sozhamannan S, Holland MY, Hall AT, et al. Evaluation of signature erosion in Ebola virus due to genomic drift and its impact on the performance of diagnostic assays. Viruses 2015, 7:3130-3154.
42. Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis 2015, 15:1034-1040.
43. Ebola virus EUA information US Food and Drug Administration, (accessed Dec 11, 2015). http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicy%20Framework/ucm182568.htm#ebola.
44. Selection and use of Ebola in vitro diagnostic (IVD) assays. Emergency guidance. WHO document WHO/EVD/HIS/EMP/15.2 WHO, (accessed Dec 11, 2015). http://apps.who.int/iris/bitstream/10665/175554/1/WHO_EVD_HIS_EMP_15.2_eng.pdf?ua=1&ua=1.
45. Southern TR, Racsa LD, Albarino CG, et al. Comparison of FilmArray and quantitative real-time reverse transcriptase PCR for detection of Zaire ebolavirus from contrived and clinical specimens. J Clin Microbiol 2015, 53:2956-2960.
46. Cherpillod P, Schibler M, Vieille G, et al. Ebola virus disease diagnosis by real-time RT-PCR: a comparative study of 11 different procedures. J Clin Virol 2016, 77:9-14.
47. Pinsky BA, Sahoo MK, Sandlund J, et al. Analytical performance characteristics of the Cepheid GeneXpert Ebola assay for the detection of Ebola virus. PLoS One 2015, 10:e0142216.
48. WHO emergency use assessment and listing procedure for EVD IVDs. Public report. Product: Liferiver™-Ebola virus (EBOV) real time RT-PCR kit. Number: EA 0009-009-00 World Health Organization, (accessed Dec 11, 2015). http://www.who.int/diagnostics_laboratory/procurement/150427_liferiver_china_public_report.pdf.Geneva,%20Switzerland.
49. Wang G, Zhang R, Han Y, et al. The evaluation of 7 commercial real-time PCR kits for Zaire ebolavirus using virus-like particle-encapsulated EBOV RNA. Diagn Microbiol Infect Dis 2015, 83:355-358.
50. Drosten C, Gottig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002, 40:2323-2330.
51. Trombley AR, Wachter L, Garrison J, et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 2010, 82:954-960.
52. Fryer JF, Heath AB, Wilkinson DE, Minor PD Collaborative study to evaluate the proposed 1st WHO International Standard for Epstein-Barr virus (EBV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2011; WHO/BS/11.2172 the Collaborative Study Group, (a ccessed Dec 11, 2015). http://apps.who.int/iris/bitstream/10665/70781/1/WHO_BS_2011.2172_eng.pdf.
53. Sollis KA, Smit PW, Fiscus S, et al. Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One 2014, 9:e85869.
54. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014, 58:e1-34.
55. Hayden RT, Preiksaitis J, Tong Y, et al. Commutability of the first World Health Organization international standard for human cytomegalovirus. J Clin Microbiol 2015, 53:3325-3333.
56. Abeynayake J, Johnson R, Libiran P, et al. Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods. J Clin Microbiol 2014, 52:3802-3804.